FDA Approves Minor Firmware Design Changes for Dexcom G5 Mobile CGM System Transmitter Component

September 20, 2026

FDA.gov USA

Overview

The U.S. FDA has granted a Premarket Approval (PMA) supplement for minor design changes to the firmware installed on the transmitter component of the Dexcom G5 Mobile Continuous Glucose Monitoring System. This approval indicates a continuous refinement of the Dexcom G5 system, ensuring its ongoing reliability and performance without altering its core functions or indications. This demonstrates Dexcom’s commitment to continuous product improvement and adherence to stringent regulatory standards.

In Depth

Key Findings

The U.S. Food and Drug Administration (FDA) has granted a Premarket Approval (PMA) supplement for minor design changes to the firmware installed on the transmitter component of the Dexcom G5 Mobile Continuous Glucose Monitoring (CGM) System. This approval ensures the system remains safe and effective for diabetes management.

Technical / Clinical Details

This PMA supplement specifically addresses ‘minor design changes’ to the firmware of the Dexcom G5 Mobile CGM system’s transmitter, which do not alter the device’s fundamental functionality, safety, or indications. These technical adjustments are presumed to include improvements in internal processing efficiency, optimization of battery life, or enhancements in data transmission stability, all aimed at boosting the system’s overall performance and reliability. Such firmware updates are a standard process in medical device lifecycle management, crucial for ensuring existing devices continue to meet current technological standards and clinical requirements. This approval reassures healthcare professionals and patients that the refined Dexcom G5 system will continue to provide high-quality glucose monitoring data.

Background & Context

Continuous Glucose Monitoring (CGM) systems have revolutionized diabetes management, reducing the need for fingerstick measurements and enabling more personalized insulin dosing. The Dexcom G5 system, as one of the earlier versions, has been widely used by many patients. The FDA’s approval of these minor design changes reflects ongoing quality assurance for previously approved CGM systems and the agency’s strict oversight of post-market product improvements. This also demonstrates medical device manufacturers’ continuous efforts to update technology to maintain product safety and efficacy.

Strategic Significance & Outlook

This approval supports the continued use of the Dexcom G5, emphasizing the importance of ongoing support for its existing user base even as newer generation CGM systems like the G6 and G7 emerge. Rapid advancements in medical technology necessitate regular improvements to existing products to ensure patients benefit from the latest innovations. It is also conceivable that these improved components could serve as foundational technologies for newer CGM platforms in the future.

Source: https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?ID=P120005S081

Get our weekly technology intelligence — free

Receive an infographic that lets you judge at a glance whether each field’s analysis report is worth reading.

Subscribe Free — Weekly Tech Intelligence

By subscribing, you’ll receive Troy-Technical’s weekly technology intelligence newsletter.